Oracle Corporation vs Viatris Inc — how do they compare? Oracle Corporation trades at $125.9 (market cap $365.96B), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Oracle Corporation is far larger — about 17.9× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| ORCL | VTRS | |
|---|---|---|
Market Cap | $365.96B | $20.50B |
Sector | Technology | Health |
52-Week High | $328.33 | $17.59 |
52-Week Low | $121.37 | $8.74 |
Enterprise Value | $495.21B | $32.71B |
Dividend Yield | 1.57% | 2.73% |
Signals from Pluang's Aura AI — not financial advice
Oracle Corporation (ORCL) trades at $125.86, up 3.7% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 21.67% net margins and consistent revenue growth. Recent AI partnerships and infrastructure investments position Oracle as a key player in the enterprise cloud and AI markets, though high valuation multiples and significant debt levels warrant caution.
Oracle presents a compelling growth story driven by AI infrastructure demand, with analyst consensus strongly bullish (65% buy ratings) and a $253.30 price target representing significant upside. Key risks include high leverage, competitive pressures, and execution challenges in capital-intensive AI expansion. The upcoming Q2 2026 earnings report on June 10 will be critical for validating the AI growth narrative.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →